SCHEMBL22636656

SCHEMBL22636656

O=[N+]([O-])c1ccc(-n2cnnn2)c(F)c1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.61
ALDH1A1 P00352 7/20 0.49
KMT2A Q03164 4/20 0.49
KCNJ1 P48048 1/20 0.44
KCNH2 Q12809 1/20 0.44
MAPT P10636 5/20 0.43
HIF1A Q16665 1/20 0.42
THRB P10828 1/20 0.41
NPC1 O15118 2/20 0.39
MEN1 O00255 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
RAB9A P51151 1/20 0.39
POLB P06746 1/20 0.39
HTT P42858 2/20 0.38
MITF O75030 1/20 0.38
NOTUM Q6P988 1/20 0.38
HSP90AA1 P07900 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29788862 0.88 LMNA (0.65) LMNAALDH1A1KMT2AKCNJ1KCNH2
SCHEMBL22637019 0.82 LMNA (0.61) LMNAALDH1A1KMT2AKCNJ1KCNH2
SCHEMBL28422920 0.79 LMNA (0.65) LMNAALDH1A1KMT2AKCNJ1KCNH2
SCHEMBL7843920 0.79 ALDH1A1 (0.49) LMNAALDH1A1KMT2AMAPTHIF1A
SCHEMBL31463575 0.78 ALDH1A1 (0.54) LMNAALDH1A1KMT2AMAPTHIF1A
SCHEMBL2659793 0.77 CYP1A2 (0.51) LMNAALDH1A1KMT2AMAPTHIF1A
SCHEMBL429447 0.76 LMNA (0.64) LMNAALDH1A1KMT2AKCNJ1KCNH2
SCHEMBL432821 0.76 LMNA (0.48) LMNAALDH1A1KMT2AKCNJ1KCNH2
SCHEMBL1131457 0.76 NOTUM (0.44) ALDH1A1KMT2AMAPTPOLBNOTUM
SCHEMBL29788843 0.75 LMNA (0.56) LMNAALDH1A1KMT2AMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240366595-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2024-11-07 US disclosed
US-12023333-B2 Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators Grey Wolf Therapeutics Limited (GB) 2024-07-02 US disclosed
US-20220347176-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2022-11-03 US disclosed
EP-3966196-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2022-03-16 EP disclosed
WO-2020225569-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2020-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366595-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS CHP1, ERAP1, QSOX1 LMNA 4878/4885ALDH1A1 1477/4885KMT2A 3032/4885
US-20220347176-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS ERAP1, CHP1, QSOX1 LMNA 4815/4885ALDH1A1 1546/4885KMT2A 2994/4885
US-12023333-B2 Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators ERAP1, CHP1, QSOX1 LMNA 4878/4885ALDH1A1 1431/4885KMT2A 2912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.